Please ensure Javascript is enabled for purposes of website accessibility

Patent Exclusivity Losses Push AstraZeneca's Q4 Profit Down 28%

By Sean Williams – Feb 6, 2014 at 9:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AstraZeneca's profit declines 28% as gains in new treatments are more than offset by key patent losses in the U.S. and unfavorable foreign currency translation.

Global pharmaceutical giant AstraZeneca (AZN 0.19%) reported its fourth-quarter results in the wee hours of the morning today, pointing to ongoing struggles as it attempts to adapt to declining sales stemming from the loss of patent exclusivity on key drugs.

For the quarter, AstraZeneca delivered a 6% decline in revenue to $6.84 billion (a 4% decline when using constant currency figures) as GAAP EPS plummeted due to a whopping $1.76 billion one-time impairment for Bydureon. Excluding this one-time charge, adjusted EPS fell 28% to $1.23 per share.

As has been the case for years now, AstraZeneca struggled with the loss of previously key drugs to generic competition, including schizophrenia and bipolar disorder drug Seroquel, whose sales dropped 22% to $372 million on increased generic competition. Top-sellers Crestor, which treats high cholesterol levels, and Nexium, which is a heartburn medication and is set to lose its exclusivity this coming May, also witnessed a drop in revenue of 8% and 3%, respectively.

Providing some spark to its top line were sales of Symbicort, which rose 11% to $976 million, as well as anticoagulant drug Brilinta (known as Brilique in the EU), whose sales more than doubled to $92 million from $38 million in the year-ago period.

Broken down by region, U.S. revenue dropped 7%, hurt by key patent losses and higher costs created by Obamacare's health care reforms, while European and rest of world revenue both declined by 2%. China and South Korea were two notable standouts, with revenue up 21% and 17%, respectively.

Looking ahead, AstraZeneca now anticipates a low-to-mid single-digit decline in revenue at a constant exchange rate in fiscal 2014, with core EPS projected to decline by the mid-teens in terms of percentage from the $5.05 reported this morning for fiscal 2013. Furthermore, AstraZeneca is forecasting 2017 revenue will be more or less in line with the $25.7 billion reported this morning for the full-year.

link

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

AstraZeneca Plc Stock Quote
AstraZeneca Plc
AZN
$68.47 (0.19%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.